Tech Company Financing Transactions
Travecta Therapeutics Funding Round
Travecta Therapeutics closed a $15 million Series A venture capital round on 5/15/2020. Investors included TKS1 and private investors.
Transaction Overview
Company Name
Announced On
5/15/2020
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series A
Investors
TKS1 (Lead Investor)
Proceeds Purpose
The proceeds from the Series A financing will be used to support Travecta's growth and advance the development of TVT-004, Travecta's lead non-opioid product targeting pain.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
545 W 25th St. 20th Floor
New York, NY 10001
USA
New York, NY 10001
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Travecta is an emerging biotech company utilizing its novel Blood-Brain Barrier Transport Platform to develop a proprietary pipeline of molecules that treat disorders of the central nervous system. The Travecta Platform leverages our proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents to the brain.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Shleifer
Chief Financial Officer
Laurent Benissan
Chief Medical Officer
Frankie Mak
Chief Scientific Officer
Mahmood Ahmed
Browse more venture capital transactions:
Prev: 5/15/2020: Jellyfish venture capital transaction
Next: 5/15/2020: Finite State venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs